Ra Pharmaceuticals, Inc.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jul 2015 | $29 M | No. 2 | $10 to $50 million | equity | SEC | |
| Feb 2010 | $10 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Ra Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2015).
SEC Form D · Jul 2015
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Jul 2015
That is all the official record says: Ra Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
10 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Morgenthaler Management Partners IX, LLC | Fund or asset manager | not stated | not stated | Held Series A, B-1 and B-2 preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Morgenthaler Venture Partners IX LP | Venture capital | not stated | not stated | Held Series A, B-1 and B-2 preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| NEA 13 GP, Ltd | Company | not stated | not stated | Held Series A, B-1 and B-2 preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| NEA Partners 13, Limited Partnership | Fund or asset manager | not stated | not stated | Held Series A, B-1 and B-2 preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| New Enterprise Associates 13 LP | Fund or asset manager | not stated | not stated | Held Series A, B-1 and B-2 preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Novartis AG | Company | not stated | not stated | Held Series A, B-1 and B-2 preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Novartis Bioventures Ltd | Venture capital | not stated | not stated | Held Series A, B-1 and B-2 preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Novo Holdings A/s | Fund or asset manager | not stated | not stated | Held Series B-1 and B-2 preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| RA Capital Healthcare Fund LP | Fund or asset manager | not stated | not stated | Held Series B-1 and B-2 preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Ra Capital Management, L.P. | Fund or asset manager | not stated | not stated | Held Series B-1 and B-2 preferred stock, 10% owner, director (Form 3, 2016) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 11 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Douglas A. Treco | Executive officer | Jul 2015 |
| Kerry A. Black | Executive officer | Jul 2015 |
| Theodore A. Laufik | Executive officer | Feb 2010 |
| Douglas A. Treco | Director | Jul 2015 |
| Edward A. Mathers | Director | Jul 2015 |
| Jason A. Lettman | Director | Jul 2015 |
| Markus A. Goebel | Director | Jul 2015 |
| Peter A. Bisgaard | Director | Jul 2015 |
| Rajeev A. Shah | Director | Jul 2015 |
| Edward W. Mathers | Director | Feb 2010 |
| James W. Broderick | Director | Feb 2010 |
| Lauren W. Silverman | Director | Feb 2010 |